{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:03:55Z","timestamp":1792796635930,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":50,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ero.2025.11.019","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T11:26:46Z","timestamp":1765366006000},"page":"475-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Occurrence of amyotrophic lateral sclerosis during TNF inhibitor treatment in inflammatory rheumatic disease. What are the relationships?"],"prefix":"10.1016","volume":"1","author":[{"given":"Eric","family":"Toussirot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Tatu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Bereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ero.2025.11.019_bib0001","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar4582","article-title":"Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study","volume":"16","author":"Kaltsonoudis","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.ero.2025.11.019_bib0002","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/kel232","article-title":"Is TNFalpha really a good therapeutic target in motoneuronal degeneration? A case of amyotrophic lat\u00e9ral sclerosis in a patient with RA receiving infliximab","volume":"45","author":"Dziadzio","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ero.2025.11.019_bib0003","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jbspin.2008.07.004","article-title":"Diagnosis of amyotrophic lateral sclerosis in a patient treated with TNFalpha blockers for ankylosing spondylitis: fortuitus association or new side effect of TNFalpha blockers?","volume":"76","author":"Loustau","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.ero.2025.11.019_bib0004","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neurol.2013.11.004","article-title":"Amyotrophic lat\u00e9ral sclerosis developing during adalimumab therapy for psoriatic arthritis","volume":"170","author":"Bougea","year":"2014","journal-title":"Rev Neurol (Paris)"},{"issue":"14","key":"10.1016\/j.ero.2025.11.019_bib0005","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1212\/WNL.0b013e3182a6cc13","article-title":"Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study","volume":"81","author":"Turner","year":"2013","journal-title":"Neurology"},{"issue":"3-4","key":"10.1016\/j.ero.2025.11.019_bib0006","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/21678421.2020.1861022","article-title":"Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study","volume":"22","author":"Cui","year":"2021","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"2","key":"10.1016\/j.ero.2025.11.019_bib0007","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1474-4422(18)30394-6","article-title":"Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies","volume":"18","author":"Beers","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.ero.2025.11.019_bib0008","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0969-9961(03)00087-1","article-title":"Message and protein-level elevation of tumor necrosis factor alpha (TNFalpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis","volume":"14","author":"Hensley","year":"2003","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.ero.2025.11.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/497080","article-title":"Autoimmunity in amyotrophic lat\u00e9ral sclerosis: past and present","volume":"2011","author":"Pagani","year":"2011","journal-title":"Neurol Res Int"},{"issue":"11-12","key":"10.1016\/j.ero.2025.11.019_bib0010","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbadis.2006.03.001","article-title":"Innate immunity in amyotrophic lateral sclerosis","volume":"1762","author":"Moisse","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.ero.2025.11.019_bib0011","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.nbd.2007.11.005","article-title":"Recombinant human TNF- binding protein-1 (rhTBP-1) treatment delays both symptoms progression and motor neuron loss in the wobbler mouse","volume":"29","author":"Bigini","year":"2008","journal-title":"Neurobiol Dis"},{"issue":"9","key":"10.1016\/j.ero.2025.11.019_bib0012","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1523\/JNEUROSCI.5253-05.2006","article-title":"Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lat\u00e9ral sclerosis","volume":"26","author":"Kiaei","year":"2006","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.ero.2025.11.019_bib0013","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/03009734.2013.785999","article-title":"Is there a link between amyotrophic lateral sclerosis and treatment with TNF-alpha inhibitors?","volume":"118","author":"B\u00f6rjesson","year":"2013","journal-title":"Ups J Med Sci"},{"issue":"11","key":"10.1016\/j.ero.2025.11.019_bib0014","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2014-205622","article-title":"ARTIS study group. No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment","volume":"73","author":"Arkema","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ero.2025.11.019_bib0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/fcp.12480","article-title":"Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis?","volume":"33","author":"Petitpain","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ero.2025.11.019_bib0016","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40264-022-01184-1","article-title":"Amyotrophic lateral sclerosis as an adverse drug reaction: a disproportionality analysis of the food and drug administration adverse event reporting system","volume":"45","author":"Gaimari","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.ero.2025.11.019_bib0017","doi-asserted-by":"crossref","unstructured":"Richardson PJ, Smith DP, de Giorgio A, et al. Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis. Transl Neurodegener. 2023;12(1):47. doi:10.1186\/s40035-023-00380-y","DOI":"10.1186\/s40035-023-00380-y"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125001193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125001193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T21:13:12Z","timestamp":1766005992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708125001193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S3050708125001193"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.019","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Occurrence of amyotrophic lateral sclerosis during TNF inhibitor treatment in inflammatory rheumatic disease. What are the relationships?","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}